Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Real World Data Collection in Subjects Treated With the FARAPULSE Pulsed Field Ablation System

NCT: NCT05501873 · ACTIVE_NOT_RECRUITING

NCT IDNCT05501873
StatusACTIVE_NOT_RECRUITING
Start Date2023-03-24
Completion2027-08-15

Brief Summary

The goal of any novel design or therapeutic strategy to treat atrial fibrillation is to restore normal sinus rhythm and to reduce or eliminate the symptoms due to rapid atrial response. Boston Scientific has developed the FARAPULSE™ Pulsed Field Ablation therapy that uses irreversible electroporation to induce cell death. This Registry is intended to obtain purely observational and prospective real world data and to provide continued evidence on the safety and effectiveness when the FARAPULSE™ pulsed field ablation System is used per hospitals' standard of care.

Frequently Asked Questions

What is Real World Data Collection in Subjects Treated With the FARAPULSE Pulsed Field Ablation System?

Real World Data Collection in Subjects Treated With the FARAPULSE Pulsed Field Ablation System is a clinical trial registered under NCT05501873. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05501873?

The current status of NCT05501873 (Real World Data Collection in Subjects Treated With the FARAPULSE Pulsed Field Ablation System) is: ACTIVE_NOT_RECRUITING.

When did Real World Data Collection in Subjects Treated With the FARAPULSE Pulsed Field Ablation System start?

Real World Data Collection in Subjects Treated With the FARAPULSE Pulsed Field Ablation System started on 2023-03-24.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑